



Videoconference – June 26, 2023

IMPORTANT NOTICE - YOU MUST READ THE FOLLOWING BEFORE CONTINUING

This presentation contains forward-looking statements, including statements regarding Company's expectations for (i) the timing, progress and outcome of its clinical trials; (ii) the clinical benefits and competitive positioning of its product candidates; (iii) **the ability of its products** to obtain regulatory approvals, commence commercial production and achieve market penetration and sales; (iv) its future product portfolio; (v) its future partnering arrangements; (vi) its future capital needs, capital expenditure plans and ability to obtain funding; and (vii) prospective financial matters regarding our business. Although the Company believes that its expectations are based on reasonable assumptions, any statements other than statements of historical facts that may be contained in this presentation relating to future events are forward-looking statements and subject to change without notice, factors beyond the Company's control and the Company's financial capabilities.

These statements may include, but are not limited to, any statement beginning with, followed by or including words or phrases such as "objective", "believe", "anticipate", "expect", "foresee", "aim", "intend", "may", "anticipate", "estimate", "plan", "project", "will", "may", "probably", "potential", "should", "could" and other words and phrases of the same meaning or used in negative form. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that may, if any, cause actual results, performance, or achievements to differ materially from those anticipated or expressed explicitly or implicitly by such forward-looking statements. A list and description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the Autorité des Marchés Financiers (the "AMF") pursuant to its regulatory obligations, including the Company's universal registration document, filed with the AMF on July 28, 2022, (the "Universal Registration Document"), as well as in the documents and reports to be published subsequently by the Company. In particular, readers' attention is drawn to the section entitled "Facteurs de Risques" on page 24 of the Universal Registration Document.

Any forward-looking statements made by or on behalf of the Company speak only as of the date they are made. Except as required by law, the Company does not undertake any obligation to publicly update these forward-looking statements or to update the reasons why actual results could differ materially from those anticipated by the forward-looking statements, including in the event that new information becomes available. The Company's update of one or more forward-looking statements does not imply that the Company will make any further updates to such forward-looking statements or other forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements.

This presentation is for information purposes only. The information contained herein does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for the Company's shares in any jurisdiction, in particular in France. Similarly, this presentation does not constitute investment advice and should not be treated as such. It is not related to the investment objectives, financial situation, or specific needs of any recipient. It should not deprive the recipients of the opportunity to exercise their own judgment. All opinions expressed in this document are subject to change without notice. The distribution of this presentation may be subject to legal restrictions in certain jurisdictions. Persons who come to know about this presentation are encouraged to inquire about, and required to comply with, these restrictions

All information in the presentation speaks only as of (1) the date hereof, in the case of information about the Company and (2) the date of such information, in the case of information from persons other than the Company. The Company does not undertake any duty to update or revise the information contained herein, publicly or otherwise. The Company has not independently verified any third-party information and makes no representation as to the accuracy or completeness of any such information.



Videoconference – June 26, 2023

Income from ordinary activities

€ 13.7 million

+64%

Operating expenses

€ 37.7 million

74% in R&D

Cash consumption

€ 21.2 million



UZEDY™

April 2023: U.S. FDA approval

May 2023: Commercial launch by Teva

Best-in-class, differentiated therapy profile

Monthly and every 2 months subcutaneous risperidone for treatment of schizophrenia


High commercial potential



Videoconference – June 26, 2023

Distinguished features thanks to BEPO®

✓ Subcutaneous injection (vs. Intramuscular)



This information should not be construed to imply any difference in safety, efficacy, or other clinical outcome.

Sources: Invega Sustenna® current Prescribing Information, Titusville, NJ: Janssen Pharmaceuticals, Inc; 2021; Risperdal Consta® current Prescribing Information, Titusville, NJ: Janssen Pharmaceuticals, Inc; 2021; UZEDY™ (risperidone) extended-release injectable suspension current Prescribing Information, Parsippany, NJ: Teva Neuroscience, Inc.



Distinguished features thanks to BEPO®

- ✓ Subcutaneous injection (vs. Intramuscular)
- ✓ Prefilled syringe
- ✓ Immediate onset of action



UZEDY™ significantly prolonged time to impending relapse compared to placebo

UZEDY™ provided continued symptom improvement in patients with schizophrenia

Sources:
Subcutaneous Risperidone (TV-46000) Efficacy and Safety in Schizophrenia: a Phase 3, Randomized, Double-Blind, Relapse Prevention Study (RISE Study) - John M. Kane, Eran Harary, Orna Tohami, Roy Eshet, Avia Merenlender-Wagner, Nir Sharon, Mark Suett, Kelli R. Franzenburg, Christoph U. Correll ;
TV-46000 Provided Continued Symptom Improvement in Patients With Schizophrenia in the Phase 3, Randomized, Double-Blind Relapse Prevention RISE Study - John M. Kane, Christoph U. Correll, Orna Tohami, Roy Eshet, Avia Merenlender-Wagner, Nir Sharon, Mark Suett, Kelli R. Franzenburg, Eran Harary

**Only 13% of U.S. treated patients
use LAIs today (200.000 out of 1,6m)**

source: Teva earnings call – Feb 2023


Annual treatment cost from \$19K to \$25K

(Comparable products, gross price)




Videoconference – June 26, 2023

Antipsychotic LAIs market – 2022



mdc-TJK – complementing UZEDY™

Number of U.S. schizophrenia patients treated with atypical antipsychotics¹ in thousands (2022)



Source:
All atypical/2ndgen. antipsychotics for schizophrenia (including all orals, injectables and other formulations, both branded and generics)

mdc-TJK


Other long-acting versions of existing generic antipsychotics have turned out to be \$1B-\$ 4B products

Existing olanzapine LAI is very little used because of safety issue leading to monitoring requirement from U.S. FDA for each injection

mdc-TJK may be the first LAI olanzapine with favorable safety profile allowing wide use



Portfolio as of June 26, 2023

FORMULATION	CMC & PRECLINICAL	PHASE 1 / 2	PHASE 3	APPROVED
				mdc-IRM Schizophrenia
			mdc-TJK Schizophrenia <i>Initiated in Jan 2023</i>	
			mdc-CWM** Post-operative pain <i>Initiated in Nov 2022</i>	
	mdc-WWM Contraception			
	mdc-GRT Organ transplant			
	mdc-STM Malaria			
	mdc-ANG Schizophrenia			
	mdc-IRM Neurosciences			
	mdc-TTG Covid-19			
mdc-TMK mdc-DPL OTHER INTERNAL & PARTNERED PROGRAMS	Lead formulation selection planned in H1 2024			

Multiple opportunities to create value in the next 24 months

